Introduction Collagenase Clostridium Histolyticum (CCH) has become a therapeutic alternative for Dupuytren disease. However, its efficacy in the medium to long term is unknown. The objective of our study is to carry out a systematic review of the studies conducted on the subject. Material and Methods Systematic bibliographic search. Analysis depending on the time of progression, looking into 2 groups with the follow-up cut-off point of 1 year. Analysis of the number of patients who reached the primary endpoint, of the mean correction in degrees, and of the proportional correction of each joint. 
Introduction
The collagenase clostridium histolyticum (CCH) used for Dupuytren Disease (DD) is a mixture of two enzymes that degrade collagen types I and III found in the abnormal tissue that constitutes this fibromatosis. The first attempt to inject substances inside the cord related to DD was made by Bassot, 1,2 in the 1960s. He coined the term "pharmacodynamical exeresis" and obtained relatively good results, published in 1969 3 , looking for a proteolytic, anti-inflammatory and anesthetic effect. The term "enzymatic aponeurotomy" was adopted in 1971 by Hueston 3 , who slightly modified the mixture for the injection. The treatment is identified as a valid alternative for patients who cannot be treated by the usual means. Using a similar technique, McCarthy obtained good results suggesting that the technique is an effective alternative as a substitute for fasciectomy. 2 Finally, the studies by Hurst and Badalamente 4, 5 established the efficacy of the treatment with an enzyme, the CCH, that allowed to break the cord in a local and minimally invasive manner. Since the publication of the first clinical trial with CCH 6 and its marketing in the USA and Europe, this drug has become more important over time 7, 8 with regard to the treatment of DD. The development of the CORDLESS clinical trial, 9,10 which involved the follow-up of patients enrolled in four previous clinical trials, has improved the level of understanding of progression in the short and medium terms. Likewise, these studies have been the basis of other publications regarding the analysis of subgroups 11 and partial results.
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Numerous clinical series and comparative studies have been published since then, providing an independent point of view regarding the clinical results obtained with the treatment. The variability among them is the norm rather than the exception, and the comparability between studies is a complex matter. 13 Although CCH is nowadays an alternative adopted by numerous hand surgeons in the treatment of DD, the rate of recurrence is unknown; thus, its status in the therapeutic arsenal compared with surgery is not clear. The scientific evidence at this time is also limited since no systematic reviews have been performed so far, and comparative studies with other techniques have been limited. The objective of our study is to carry out a systematic review covering all these studies, which evaluate independent studies and demonstrates the result of the CCH treatment since its commercialization aimed at assessing the efficacy of the treatment.
Material and Methods
A structured bibliographic search was performed in the PubMed, Google Scholar, Ovid and Web of Science databases
Conclusions The results indicate a satisfactory response to CCH treatment maintained in the short and medium term. The recurrence rate is uncertain given the available data.
Resumen
Introducción La Colagenasa Clostidium Histolyticum se ha convertido en una alternativa terapéutica para la enfermedad de Dupuytren. Sin embargo, se desconoce su eficacia a medio y largo plazo. El objetivo de nuestro trabajo consiste en la realización de una revisión sistemática de los trabajos realizados. Material y Método Búsqueda bibliográfica sistemática. Análisis dependiendo del tiempo de evolución considerándose dos grupos con el punto de corte de seguimiento un año. Análisis del número de pacientes que alcanzaron el objetivo primario, la corrección media en grados y la alcanzada por cada articulación. We initially included all designs of cohort studies, clinical trials, case-control and case series published in English, Spanish, German, French and Italian; and those in which patient follow-up was specified for at least 30 days. Only studies that included patients diagnosed with Dupuytren contracture susceptible to surgical intervention with an initial contracture degree equal to or greater than 20°, and with at least one group of patients treated with CCH were considered. Reanalyzes of previous series, or those that did not provide data for the analysis, were excluded.
A structured form was used for the extraction and definitive collection of the data from the studies selected independently by two authors. The discrepancies that emerged upon comparing the results of both authors were resolved by a third author. To assess bias in the studies, we used the strategic orientation of business enterprises (STROBE) scale, with two researchers scoring each of the selected studies and using the mean of the two to assess their quality. Any disagreements were resolved through consensus with a third researcher.
The main variables collected from each study were the features and the design of the study, the interventions performed, the CCH doses utilized, the number of injections per patient, the extension time, and the criteria regarding severity and results, as well as the follow-up time. Finally, the funding from each study, if any, was collected. In clinical trials and comparative observational studies, only the clinical results of the group of patients treated with CCH were taken, and they were taken as a sample reference.
An analysis of the existing literature was conducted with regard to the results, taking into consideration two groups with a follow-up cut-off of 1 year. The clinical results were assessed based on three parameters: A) The number of patients who have reached the primary end point established in the CORD studies 6, 14 (final extension after treatment between 0-5°) stating the result in total absolute percentage of joints that have reached the objective; B) The assessment of the mean correction of each joint in degrees was evaluated, defined as the result of the degree of initial contracture minus the degree of final contracture; and C) Data regarding the correction ratio of the treated joint was also collected. If an article stated the results of two different modes, both have been included. An assessment of the recurrences over time has been made in the studies intended for that purpose, 9,10 as well as in all those that cited them in their series. Finally, the concept of "noneffective" treatment in the series has been assessed. The missing data in the tables explain the lack of direct correlation between results (A þ B6 ¼C, as in one study overall results The immediate measures to be implemented following treatment with CCH is a controversial issue. Therefore, in the articles analyzed, usage of orthosis and referrals to a physiotherapy protocol following CCH administration have been reviewed. In the final chapters, we analyzed both the recurrences and the treatment failures, commonly considered in the literature as "non-responders."
Results

Search Results
Total 598 articles were obtained, of which only 240 studies have met the inclusion criteria. After removing duplicates, the elimination followed the exclusion criteria following the reading of the review summary, clinical cases, letters to the director, editorials and meeting summaries. Total 61 articles were obtained for analysis. These studies were reviewed through a complete reading of the article. Eleven studies were eliminated for a variety of reasons: 6 due to insufficient data on clinical outcomes (including cost studies), 3 due to cross-references to previous studies (subgroup analysis), and 2 due to exclusive references to results related to thumbs (excluded from the analysis of the CORD study 6, 14 ). In the end, 50 publications were analyzed (►Fig. 1). The interobserver assessment performed using the STROBE scale of the included articles has shown great homogeneity among the researchers (kappa > 0.85).
Results of the Clinical Studies
The main features of the selected studies are shown in ►Table 1. The monitoring of progression corresponding to the 3-year CORDLESS study has been included in the series, 9 taking into account that the patients associated with the CORD I, CORD II, POINT I and POINT II studies have been excluded for the calculation of demographic data. 6, 14, 15 The POINT X study was also excluded 16 because it was conducted in a subgroup of patients associated with The mean age of the patients was 65.2 years (range 61.0-70.0). Male patients corresponded to 85% of the patients in the studies (mean 92.5, range 7-542). Thirty-three series were developed in a single center and 18 studies were multicenter projects. With regard to the temporal evolution, 36 studies were prospective and 15 were retrospective.
We have found a great heterogeneity of studies with many methodological variations. The two clinical trials corresponded to the CORD I 6 and CORD II 14 clinical trials performed in the USA and Australia, respectively, and which compared the effect of CCH over placebo. The nine casecontrol series compared the effect of CCH with that of surgery through fasciectomy [19] [20] [21] [22] [23] or with needle aponeurotomy. [24] [25] [26] [27] Even though most of the studies were based on clinical series with a time-based follow-up, they ranged from cost studies, regarding "unusual" cords (natatory, Y-shaped or crow-foot cords) were specified in the same way as Verheyden.
39
Several studies [40] [41] [42] assessed the impact with respect to the extension time following consistent administration of treatment.
The inclusion and exclusion criteria for the studies included were based on the drug's fact sheet. All patients included presented with a minimum initial contracture of 20°in the PIP or MCP joints. Studies that have strictly followed the CORD criteria have limited the maximum degree of flexion also included in the study. The follow-up criteria showed a great deal of heterogeneity. After reading the articles, 26 studies, directly or indirectly, followed the criteria of the CORD clinical trials to demonstrate their results. On the other hand, 5 followed the Tubiana classification, 18,28,43-45 and 1 followed its own criteria. 30 The remaining 19 have not specified their follow-up criteria. The administered dose was standard in all studies, except for two studies that used double dose on the same hand at a time, 17, 46 and four that used the standard dose plus the amount remaining in the vial in various formats.
39,47-49
Twenty-three studies followed an injection protocol in which they allowed one to three infiltrations per joint and patient, four 25,29,38,47 studies used one or two injections, even though they followed the CORD protocols, and presumably if it were needed, they would have used three, and the rest used a protocol of one injection for an infiltration of a joint. In the studies that specified how many vials were used per joint, the mean was 1.23 (range 0.8-1.6; SD: 0.36), with only one study having used less than one vial per joint, 50 and with 
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The systematic implementation of a physiotherapy protocol after CCH treatment is another controversial point regarding the outcomes. Thirteen articles indicate that patients were systematically referred to an established physiotherapy protocol or that monitoring was performed by specialist physiotherapists, 
Clinical Findings
The studies analyzed indicate a timeline regarding the progression time. In spite of not having a formal indication as to the progression time, the studies mark a before and an after with a timeline of less or more than 1 year. Studies with a course of less than 1 year set out to assess the clinical effectiveness of the treatment or some of its modifications (if the treatment actually works by reducing contracture in DD), and the studies that took 1 year or longer try to assess the effectiveness of the treatment (if the achieved effect is maintained over time). To calculate the clinical outcomes (►Appendix A), data from studies that lasted less than 1 year (►Table 3) have been taken into account together with the figures from the intermediate results of the studies that took 1 year or longer (►Table 4). 
Studies that Cover Less than 1 Year of Progress
Recurrences
Apart from the CORDLESS studies, 9,10 few studies have collected the incidence of recurrences in their results. 19, 30, 34, 35, 37, 48, 58 The rate of recurrence during the follow-up period ranged from 1.7% in 1 year 37 to 59% in the series by Sood 30 within the same period, but with its own criteria of recurrence. Upon eliminating these two values, this rate ranged between 7-28%. All the articles that mentioned the rate of recurrence had a follow-up between 6 and 18 months. We should keep in mind that the series by Bear
34
had a 28% recurrence rate in patients previously treated with CCH after 1 year of follow-up. The CORDLESS studies were designed as observational clinical studies for assessing the rate of recurrence over time. These follow-ups were published at 3 9 and 5 years. 10 The recurrence rate was calculated based on the secondary end point (at least 50% of correction since the initial contracture), demonstrating a recurrence rate of 38% (28% for the MCP and 58% for the PIP) at 3 years, and 48% (39% for the MCP and 65% for the PIP) at 5 years. Peimer indicates that 75% of the 
Discussion
Collagenase clostridium histolyticum is currently a therapeutic alternative for DD both in Europe 8 and the USA. However, the heterogeneity of publications has been more the norm rather than the exception in studies related to CCH. Even though virtually all studies have maintained a standard minimum contracture with which to begin the treatment (20 degrees), some have slightly increased this to 30 degrees. Other data, such as the loss of extension limit (initially set at 100 degrees for the finger), the variation in severity criteria with regard to adoption of own criteria rather than any other DD classification, show the heterogeneity in publications, as is common in publications related to Dupuytren surgery.
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The measurement of results is another example: the CCH treatment is performed at a joint level in an isolated manner; with the rupture of the cord, a compensatory correction of the adjacent joint of the same finger can be produced. Measuring both joints together after the treatment of only one of them constitutes an error that causes bias in clinical studies, as the correction of a joint can be masked by the affectation or the retraction of the adjacent finger.
62 Likewise, the inclusion of untreated joints in the results, when they present baseline contracture, worsens the final result if a joint finger assessment (MCP þ PIP) is done. In fact, to mitigate these shortcomings, in CORD studies the results are presented in two modes: on the one hand in terms of the correction of the treated joint, and on the other in the form of "range of movement" (ROM). 6,14,54 Different forms of measurement (ROM, passive extension deficit [PED], isolated joints) are adopted in the studies, which complicate the comparability of results between the studies (►Table 1).
Clinical results indicate that full extension of the fingers has been achieved in $ 50% of the cases maintained for a year, and the mean reduction in contracture for all patients is at around 75%, indicating a remarkable effectiveness of the treatment. The results of our study may seem contradictory with a higher reduction in digital contracture in studies lasting over 1 year than in studies covering less than 1 year of progress, but the heterogeneity of published papers and the lack of homogeneity between the protocols used 63 explain this variation, which does not invalidate the final result. The fact that a greater number of patients have reached the primary end point in studies lasting more than 1 year is due, in part, to the fact that many of these studies have been funded by or related to the company that markets the drug, which is why the patient selection criteria, the surgeon's experience or the protocol for patient maintenance, minimizing the losses of individuals with a positive result, may be regarded as biased. 9, 34, 35, 37, 48, 54, 60 With regard to joint treatment, the demonstrated results concur with many of the series published. The outcome for the MCP joint is better than the outcome for the PIP, and the recurrences of the latter are also much more frequent. The data presented does not allow for a study of the severity of the affected joint as some authors do 9, 14, 46, 57 ; the analyzed data indicate that a more severe initial contracture signifies a worse outcome for the treatment, more specifically for the PIP. With respect to the issue of recurrence, the lack of studies in the medium and long term prevents an objective assessment; however, the CORDLESS studies show a clear tendency toward recurrence with an overall rate of 48% at 5 years.
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Garcia-Olea 64 quantifies the deterioration of the patients in their series at 1.5 degrees per month. Physiotherapy protocols have not been included in clinical trials; thus, the improvement or sustainability of treatment with them cannot be assessed. Although the use of night splints is indicated, many studies have avoided this adjunctive measure, possibly due to poor compliance of the patients, 41 and the discomfort it causes over an extended period of time. These two measures, without a doubt, are the most variable in the studies analyzed. One of the first comparative clinical studies 32 actually assessed the use of these measures for treatment with CCH and concluded that their apparent benefit is in the short term.
Among the main problems that are not taken into account in the analyzed series is the rate of poor and "non-effective" outcomes. The same analysis is not performed on these patients as it is performed on those with good outcomes. There is currently no explanation as to why some patients do not respond to the treatment.
Among the limitations of our study, the main one is the possibility of biases in terms of data collection. Injection on a joint and the measurement of the full result on the affected finger is in itself a bias that some of the cited papers comment on, and it has made it difficult to compare this technique with the surgical procedures (partial fasciectomy), where traditionally the whole radius is treated. The results are usually expressed as a difference in degrees between the initial and final results with a range in each value. While obtaining the difference between both results for the assessment of the correction achieved is very simple, it is practically impossible to evaluate the standard deviation of the sample. This prevents large-scale statistical studies from being conducted, and thus constitutes the main limitation of our study. Unfortunately, these limitations are insurmountable and evident in the analysis of bibliography. 
